Palisade Bio, Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company, announced that an abstract detailing preclinical data for its lead drug candidate, LB1148, has been selected for a poster presentation at Digestive Disease Week (DDW) 2026. The conference will be held from May 16-19, 2026, in Washington, D.C.
The abstract, titled "LB1148, a Novel Oral Serine Protease Inhibitor, Accelerates Return of Postoperative Gastrointestinal Function in a Preclinical Model," will be presented during the conference. LB1148 is an oral liquid formulation of a broad-spectrum serine protease inhibitor designed to neutralize digestive enzymes and accelerate the return of normal gastrointestinal function following surgery.
DDW is a premier international conference for physicians, researchers, and industry professionals in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. The selection of the abstract for presentation indicates peer-reviewed interest in the company's research on postoperative ileus, a common complication of abdominal surgery.
Palisade Bio's CEO, J.D. Finley, stated that the presentation underscores the company's commitment to advancing treatments for gastrointestinal recovery. The company is currently conducting a Phase 3 clinical trial, ADVANCE, to evaluate LB1148's efficacy in improving return of bowel function after bowel resection surgery.
